Business
Immuno-Oncology Summit Europe 2017
Immuno-Oncology Summit Europe 2017.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 8784Z Scancell Holdings Plc 20 March 2017 \n\n20 March 2017\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nScancell to present at the Immuno-Oncology Summit Europe 2017\n \nProfessor Lindy Durrant, Scancell's CSO, to chair and present in a session entitled:\n\"Combining Checkpoint Inhibitors with Other Modalities\"\n \nScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that it will be participating in the upcoming Inaugural Combination Immunotherapy meeting, part of the Second Annual Immuno-Oncology Summit Europe 2017, 20-24 March 2017 at the Hilton Canary Wharf, London, UK, alongside other industry leaders from Merck, Sharp and Dohme, Bristol-Myers Squibb and Cancer Research UK. \n \nProf. Lindy Durrant, Ph.D., Chief Scientific Officer of Scancell and Professor of Cancer Immunotherapy, University of Nottingham, will chair the session entitled: \"Combining Checkpoint Inhibitors with Other Modalities\" on Thursday 23 March 2017. Prof. Durrant is also featured as a presenter in this session and will deliver a presentation entitled: \"Combinations of Novel Vaccines with Checkpoint Inhibitors\", scheduled to take place at 14.20 GMT. \n \nDuring the presentation, Prof. Durrant will discuss progress made with Scancell's two cancer immunotherapy platforms, ImmunoBody® and Moditope®.\n \nImmunoBody® utilises both cross- and direct-presentation to increase T-cell avidity by 100 fold. In Phase 1/2 trials, it induced T-cell responses, tumour regression and long term survival. In combination with checkpoint inhibitors, it induced 100% tumour regression in established models. Phase 2 trials of ImmunoBody® vaccines in combination with checkpoint inhibitors in melanoma and non-small cell lung cancer are being planned. \n \nModitope® stimulates powerful anti-tumour T-cell responses against neo-epitopes produced by enzymes induced by cellular stress. First-in-man clinical studies for breast cancer, ovarian cancer and osteosarcoma are anticipated to commence in 2018. \n \nFor Further Information: \n \n\n\n\n\nDr John Chiplin, Executive Chairman\nDr Richard Goodfellow, CEO\n\n\nScancell Holdings Plc\n \n\n\n+1 858 900 2646\n+44 (0) 20 3727 1000\n\n\n\n\n\n\n\n\n\n\n\n...